BRPI0513278A - uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton - Google Patents

uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton

Info

Publication number
BRPI0513278A
BRPI0513278A BRPI0513278-9A BRPI0513278A BRPI0513278A BR PI0513278 A BRPI0513278 A BR PI0513278A BR PI0513278 A BRPI0513278 A BR PI0513278A BR PI0513278 A BRPI0513278 A BR PI0513278A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
cell death
producing
activation therapy
Prior art date
Application number
BRPI0513278-9A
Other languages
English (en)
Inventor
Bipin Chandra Muljibhai Patel
Original Assignee
Psimei Pharmaceuticals Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psimei Pharmaceuticals Plc filed Critical Psimei Pharmaceuticals Plc
Publication of BRPI0513278A publication Critical patent/BRPI0513278A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

USO DE UM COMPOSTO, COMPOSTO, COMPOSIçãO FARMACêUTICA, PROCESSO PARA PRODUZIR UM COMPOSTO, E, MéTODO PARA CAUSAR A MORTE CELULAR ATRAVéS TERAPIA DE ATIVAçãO POR FóTON A presente invenção refere-se ao uso de um composto da fórmula (I) na manufatura de uma composição farmacêutica para a morte celular por terapia de ativação por fóton e o uso dos compostos na prevenção e/ ou tratamento de câncer.
BRPI0513278-9A 2004-07-13 2005-07-08 uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton BRPI0513278A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0415663.4A GB0415663D0 (en) 2004-07-13 2004-07-13 Compound
PCT/GB2005/002693 WO2006005924A1 (en) 2004-07-13 2005-07-08 Porphyrin derivatives and their use in photon activation therapy

Publications (1)

Publication Number Publication Date
BRPI0513278A true BRPI0513278A (pt) 2008-05-06

Family

ID=32893498

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513278-9A BRPI0513278A (pt) 2004-07-13 2005-07-08 uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton

Country Status (12)

Country Link
US (1) US7816518B2 (pt)
EP (1) EP1773324B1 (pt)
JP (1) JP2008506675A (pt)
KR (1) KR20070054636A (pt)
CN (1) CN101018551A (pt)
AU (1) AU2005261561A1 (pt)
BR (1) BRPI0513278A (pt)
CA (1) CA2573609A1 (pt)
GB (2) GB0415663D0 (pt)
RU (1) RU2007105233A (pt)
WO (1) WO2006005924A1 (pt)
ZA (1) ZA200701175B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0415663D0 (en) 2004-07-13 2004-08-18 Psimei Pharmaceuticals Plc Compound
CN101160354B (zh) * 2005-04-18 2010-12-29 前田浩 高分子型癌症治疗用药及其制造方法
US8287839B2 (en) * 2006-12-04 2012-10-16 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US8324342B1 (en) * 2007-06-13 2012-12-04 Sandia Corporation Porphyrin coordination polymer nanospheres and nanorods
TWI458512B (zh) 2008-02-21 2014-11-01 Immunolight Llc 利用電漿子增強之光譜療法（ｐｅｐｓｔ）及激子－電漿增強之光療法〈epep〉治療細胞增生病症之組合物及產生自體疫苗之系統
WO2013009688A1 (en) 2011-07-08 2013-01-17 Bourke Frederic A Phosphors and scintillators for light stimulation within a medium
CN105288619A (zh) * 2008-04-04 2016-02-03 免疫之光有限责任公司 用于原位光生物调节的非侵入性系统和方法
US20090275548A1 (en) * 2008-04-18 2009-11-05 Thomas Lewis Compounds and methods for activated therapy
CN105524949A (zh) * 2008-11-17 2016-04-27 希乐克公司 生物量加工
JPWO2011099602A1 (ja) * 2010-02-12 2013-06-17 学校法人日本大学 ポルフィリン誘導体および放射線力学療法におけるその使用
KR101932149B1 (ko) * 2010-10-06 2018-12-26 앨루스 사이언스, 인코포레이티드 포르피린을 이용한 신경퇴행성 질환 치료
DE102010056443A1 (de) * 2010-12-28 2012-06-28 Universität Bremen Chlorin-Derivate und deren Verwendung
CN102499924B (zh) * 2011-11-23 2013-07-24 中国医学科学院生物医学工程研究所 二乙撑三胺五乙酸或乙二胺四乙酸或胺三乙酸修饰卟啉的用途
GB201208548D0 (en) 2012-05-15 2012-06-27 Pci Biotech As Compound and method
EP3061762A1 (en) * 2015-02-26 2016-08-31 Universiteit van Amsterdam Photosensitizers
CN105503918A (zh) * 2015-12-08 2016-04-20 南京林业大学 一种含二氧杂戊硼基卟啉锌配合物及其制备方法
WO2019117457A1 (ko) 2017-12-12 2019-06-20 한국과학기술원 다공성 포르피린 고분자 및 이를 이용한 귀금속 원소의 회수 방법
KR102193582B1 (ko) * 2017-12-12 2020-12-22 한국과학기술원 다공성 포르피린 고분자 및 이를 이용한 귀금속 원소의 회수 방법
CN109679110B (zh) * 2018-12-25 2020-10-09 北京科技大学 一种基于菌绿素的纳米金属-有机框架光敏剂及制备方法
CN110684531B (zh) * 2019-10-09 2022-04-01 浙江理工大学 一种二硫化钼量子点负载四苯基锆卟啉纳米片的光敏传感材料的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489716A (en) 1987-01-02 1996-02-06 Sun Company, Inc. (R&M) Reactions catalyzed by haloporphyrins
US4959356A (en) 1989-05-26 1990-09-25 The United States Of America As Represented By The United States Department Of Energy Porphyrins for boron neutron capture therapy
JP3191223B2 (ja) * 1991-10-04 2001-07-23 株式会社光ケミカル研究所 ポルフィリン誘導体とその用途
JP3253663B2 (ja) * 1992-01-20 2002-02-04 タマ生化学株式会社 放射線増感剤
US5877165A (en) * 1995-11-02 1999-03-02 Brookhaven Science Associates Boronated porhyrins and methods for their use
WO1998050386A1 (en) * 1997-05-07 1998-11-12 The University Of British Columbia A new class of benzoporphyrin derivative photoactive compounds
CA2448562A1 (en) * 2001-05-31 2002-12-05 Miravant Pharmaceuticals, Inc. Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
WO2002098417A1 (en) * 2001-06-06 2002-12-12 Brookhaven Science Associates Novel metalloporphyrins and their uses as radiosensitizers for radiation therapy
GB0227259D0 (en) 2002-11-21 2002-12-31 Photobiotics Ltd Porphyrin derivatives
US7378520B2 (en) 2004-07-08 2008-05-27 North Carolina State University Synthesis of porphyrins designed for attachment to electroactive surfaces via one or more carbon tethers
GB0415663D0 (en) 2004-07-13 2004-08-18 Psimei Pharmaceuticals Plc Compound

Also Published As

Publication number Publication date
CA2573609A1 (en) 2006-01-19
ZA200701175B (en) 2008-11-26
GB0702696D0 (en) 2007-03-21
US20080039436A1 (en) 2008-02-14
EP1773324B1 (en) 2015-04-01
AU2005261561A1 (en) 2006-01-19
KR20070054636A (ko) 2007-05-29
CN101018551A (zh) 2007-08-15
EP1773324A1 (en) 2007-04-18
JP2008506675A (ja) 2008-03-06
RU2007105233A (ru) 2008-08-20
GB2433070A (en) 2007-06-13
GB0415663D0 (en) 2004-08-18
US7816518B2 (en) 2010-10-19
WO2006005924A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
BRPI0513278A (pt) uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
BRPI0712631B8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
BRPI0618552B8 (pt) compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos
BRPI0514841A (pt) inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores
EA200700501A1 (ru) Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества
BRPI0409198A (pt) derivados quinolin-2-ona para o tratamento de doenças de vias aéreas
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
BRPI0508561A (pt) 3-'4-heterociclil-1,2,3-triazol-1-il-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crÈnicas
BRPI0410238A (pt) compostos orgánicos
BRPI0608840B8 (pt) composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
BRPI0509912B8 (pt) compostos, processo para a preparação dos mesmos, composição farmacêutica, e, uso de um composto
NO20091605L (no) Pyridinonforbindelser
DK1853602T3 (da) Kemiske forbindelser
UY29648A1 (es) Derivados de piridopirimidina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
BRPI0312398B8 (pt) derivado de 1,3-difenilprop-2-en-1-ona substituído, processo de preparação de compostos, composição farmacêutica e utilização de pelo menos um derivado de 1,3-difenilprop-2-en-1-ona substituído
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BRPI0508177A (pt) composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação
GEP20125643B (en) Aurora kinase modulators and method of using same
BRPI0806400A8 (pt) composto, composição farmacêutica, produtos, usos de pelo menos um composto, método in vitro, kit, ligantes e processo de preparação de um composto
BRPI0615614A2 (pt) compostos orgánicos

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 7A E 8A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A, 9A, 10A, 11A, 12A, 13A, 14A E 15A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.